相关临床试验
779
60 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1963
进行中（未招募）
30
3.9%
已完成
449
57.6%
Enrolling By Invitation
8
1.0%
尚未招募
22
2.8%
招募中
160
20.5%
暂停
3
0.4%
终止
78
10.0%
Unknown
9
1.2%
撤回
20
2.6%
暂无批准数据
- A Nature study led by Mount Sinai researchers identifies Sst-Chodl neurons in the cerebral cortex as an active driver of sleep rather than a passive follower of deep brain centers. - Sst-Chodl neurons make up roughly 0.2% of cortical neurons but send long-range signals capable of synchronizing activity across large areas of the brain. - Activating these neurons slowed and synchronized neocortical electrical activity and was sufficient to make mice fall asleep more readily and sleep longer. - The neurons are conserved across hundreds of millions of years of evolution, from amphibians and reptiles to humans, suggesting a fundamental function.
- Red and near-infrared light penetrate deeper into skin than other wavelengths and appear to boost cellular energy and collagen production, but evidence for at-home devices remains limited. - A manufacturer-funded trial of 59 middle-aged adults found 86% of combination laser-and-LED mask users had slight crow's feet reduction versus 17% with a placebo mask. - Experts say safety data for red-light therapy is stronger than efficacy data, and people with photosensitive disorders or light-sensitizing medications should avoid it. - Dermatologists advise checking FDA clearance, disclosed device specifications, and eye protection, and caution that sunscreen and tretinoin likely offer better returns.
- Fareon announced a new bioRxiv paper linking its noninvasive Microtesla Magnetic Therapy (MMT) to protein markers for reduced inflammation, increased repair, and lower predicted brain age. - The exploratory plasma proteomics analysis examined over 10,500 circulating proteins from 30 adults with Long COVID–associated cognitive impairment in a randomized, sham-controlled study. - Participants receiving MMT showed molecular signatures consistent with reduced inflammatory biology and increased repair pathways, alongside a directional reduction in Predicted Brain Age measured by Vero Bioscience's OrganAge platform. - Findings provide early evidence of slowing or reversing biological brain aging and support the rationale for Fareon's upcoming RECLAIM clinical program, though validation in larger studies is required.
- Pacibekitug, a long-acting anti-IL-6 monoclonal antibody, produced dose-dependent and sustained reductions in hs-CRP through day 180 in patients with stage 3–4 chronic kidney disease at high inflammatory risk. - Median time-averaged hs-CRP change was −76% to −89% across pacibekitug dose groups versus +7% with placebo (all p<0.0001), with reductions also seen in fibrinogen and lipoprotein(a). - The phase II TRANQUILITY trial found pacibekitug well tolerated, with only 1.9% discontinuation and no clear dose-related safety signals. - Findings support a larger, longer-term phase III trial to determine whether these biomarker effects translate into improved cardiovascular outcomes.
- The phase 1/2 ASPIRE trial combined anastrozole, palbociclib, trastuzumab and pertuzumab as first-line therapy for treatment-naive hormone receptor-positive, HER2-positive metastatic breast cancer. - The single-arm study reported a 97% clinical benefit rate (95% CI, 82%-99%) with median progression-free survival of 24.9 months and 93% of patients alive at 39.4 months. - Investigators reported no unexpected safety signals, with neutropenia, leukopenia, diarrhea and anemia the most common adverse events and only one patient discontinuing treatment. - Researchers at the Icahn School of Medicine at Mount Sinai cautioned the 29-patient study is hypothesis-generating and requires larger randomized trials comparing the regimen with standard therapy.
- A nationwide study tracking over 3,000 radiation oncology clinics from 2018 to 2025 reveals that freestanding practices were 56% more likely to close than hospital-affiliated sites, with rural communities disproportionately affected. - As of 2025, 68.5% of U.S. counties—home to approximately 50.8 million people—had no radiation oncology practice site, with these areas showing higher poverty and uninsured rates. - The loss of a single rural clinic frequently leaves patients without local access to radiation therapy, forcing hours of daily travel for treatment that requires five visits per week over several weeks. - Researchers call for policy interventions and improved reimbursement models to preserve access in underserved communities before gaps widen further.
- The Icahn School of Medicine at Mount Sinai has received a five-year, $7.2 million NIAID grant to establish the INROADS center focused on personalized treatment strategies for peanut allergy. - INROADS aims to identify biological mechanisms and biomarkers that predict which patients are most likely to benefit from desensitization therapies, including peanut oral immunotherapy and omalizumab. - The center includes two major research projects—MICRO-TRACK and SPADE—leveraging advanced immune profiling, transcriptomics, and machine learning to uncover molecular signatures of treatment success. - Peanut allergy affects nearly 2% of adults and up to 5% of children in some U.S. regions, with prevalence tripling in recent decades, underscoring the urgent need for precision medicine approaches.
- Researchers used human cerebral organoids to demonstrate that Ebola virus can productively persist in brain tissue for up to 120 days, infecting neurons, astrocytes, and microglia. - The study found that Ebola virus spreads via both cell-to-cell transmission and traditional budding, while late-stage infection triggers pro-inflammatory cytokine responses that fail to clear the virus. - Defective viral genomes and specific mutations identified in persistently infected organoids may explain how the virus evades immune detection and maintains long-term infection. - The findings align with clinical observations of Ebola survivors who develop meningoencephalitis and ocular inflammation months after recovery, highlighting the model's translational relevance.
- A multicenter randomized controlled trial across 13 pediatric transplant centers evaluated the Medication Level Variability Index (MLVI) to flag adolescents and young adults at elevated risk for liver transplant rejection due to medication nonadherence. - The study screened over 3,000 health records and enrolled 148 high-risk participants, finding that routine MLVI use substantially reduced overall rejection rates to levels typically seen in low-risk patients. - Patients receiving a two-year remote behavioral intervention experienced approximately half as many rejection-related events and re-transplants compared to those receiving standard care. - Researchers strongly support incorporating MLVI into routine clinical practice, enabling a shift from reacting to rejection to preventing it using data already available in electronic health records.
- A pilot study of 43 patients found that multiparametric MRI before kidney tumor surgery can predict renal function decline and CKD development one year after nephrectomy. - Combining MRI-derived biomarkers with standard clinical assessments significantly improved identification of high-risk patients compared to conventional tools alone. - Both poorly functioning kidneys and kidneys working exceptionally hard before surgery were associated with greater risk, suggesting reduced "kidney reserve" may be detectable via imaging. - The research, led by Dr. Mira Liu at Mount Sinai, received the W.S. Moore Award and points toward more personalized presurgical risk assessment using existing clinical imaging tools.
